Advertisement
INCY vs JNJ
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- INCY trades at a lower trailing P/E of 15x with no dividend, reflecting its biotech growth profile, while JNJ offers a 2.16% yield and P/E of 22x for stability.
- JNJ has outperformed YTD with +16.8% gains versus INCY's +2.9%, driven by FDA approvals and pipeline advances.
- Recent revenue growth stands out for INCY at 28% in Q4 2025 from Jakafi and Opzelura, but shares faced pressure from valuation concerns and patent risks.
- JNJ's diversified Innovative Medicine and MedTech segments provide lower beta (0.33) and consistent momentum amid market volatility.
- Market caps differ sharply: JNJ at $579B dwarfs INCY's $19B, highlighting scale versus specialized oncology focus.
- AI analysis favors JNJ for relative stability and catalysts in recent market activity.
Introduction
This stock comparison between INCY and JNJ examines two healthcare giants with distinct profiles: Incyte Corporation, a biopharmaceutical innovator in oncology and inflammation, versus Johnson & Johnson, a diversified leader in pharmaceuticals and medical technologies. Traders seeking growth in specialized therapies may eye INCY, while investors prioritizing stability, dividends, and broad exposure favor JNJ. In the current market environment, marked by pipeline advancements and sector rotations, understanding their relative performance, sentiment shifts, and risk-reward trade-offs aids informed positioning in healthcare stock comparisons.
INCY Overview and Recent Performance
Incyte Corporation (INCY) is a global biopharmaceutical firm specializing in oncology, hematology, and inflammation therapies, with key products like Jakafi (ruxolitinib) for myeloproliferative neoplasms and Opzelura for dermatological conditions. In recent market activity, shares have traded around $96, down from a 52-week high of $112 amid a roughly 6.5% pullback over the past month. This weakness follows Q4 2025 revenue surging 28% to $1.51 billion, propelled by Jakafi and Opzelura sales, with full-year revenue at $5.14 billion. Sentiment reflects mixed fair value signals and concerns over Jakafi patent expiration risks, tempered by optimism around pipeline expansion and upcoming conferences. YTD gains stand at +2.9%, with a market cap of $19 billion and beta of 0.84 indicating moderate volatility relative to biotech peers.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) operates through Innovative Medicine and MedTech segments, delivering therapies in oncology, immunology, and devices for cardiovascular and orthopedics. Shares hover near $240, off a 52-week high of $252 but up significantly from $142 lows, reflecting resilience. Recent weeks saw boosts from FDA approvals like TECVAYLI for multiple myeloma and Bank of America raising its price target to $253 on pipeline strength. YTD performance reaches +16.8%, outpacing the sector, supported by diversified revenue of $94 billion TTM and strong free cash flow. Market sentiment favors its low beta of 0.33 and consistent execution, though antitrust settlements and unit sales rumors added noise. With a $579 billion market cap, JNJ embodies defensive healthcare positioning.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top-performing AI trading bots from hundreds available, which collectively trade thousands of tickers across stocks, ETFs, and crypto using diverse strategies like trend following, swing trading, and hedging. Only those excelling in current market conditions—factoring volatility, momentum, and sector rotations—earn a spot, with AI dynamically analyzing performance metrics. Highlighted bots show annualized returns from +19% to over +134%, win rates of 60-95%, profit factors up to 25+, and trade durations from hours to months; examples include Aerospace GE (15min) at +80% annualized with 82% win rate and multi-ticker portfolios like semiconductors/oil at +94% across 8 tickers. These vary by timeframe (5min to 60min AI/ML), risk profiles, and focus (e.g., biotech BIB at +24% with 95% win rate). Explore Trending AI Robots to identify bots suited to your trading style and market outlook.
Head-to-Head Comparison
INCY and JNJ contrast sharply in business models: Incyte's oncology-centric pipeline drives higher growth potential but elevates risks from patent cliffs like Jakafi's 2028 expiration, while Johnson & Johnson's scale across pharma and MedTech ensures steady revenue diversification. Recent momentum favors JNJ with superior YTD returns and lower volatility (beta 0.33 vs. 0.84), bolstered by multiple FDA nods versus INCY's revenue beats offset by forecast concerns. Risk factors include competition and regulatory hurdles for both, but INCY faces greater pipeline dependency. Sector exposure tilts biotech innovation for Incyte against JNJ's broad healthcare stability. Market sentiment leans toward JNJ's reliability in choppy conditions, trading at a premium P/E reflecting its dividend aristocrat status, while INCY offers value for growth-oriented relative performance plays.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ over INCY, based on superior trend consistency, lower risk via diversification, recent catalysts like TECVAYLI approval, and stronger relative positioning in recent market activity. While INCY's revenue momentum and valuation appeal probabilistically support upside in biotech rallies, JNJ's stability edges it out for balanced portfolios amid volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a StrongBuy and JNJ is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 1 bullish TA indicator(s).
- INCY’s TA Score: 4 bullish, 4 bearish.
- JNJ’s TA Score: 1 bullish, 6 bearish.
Price Growth
INCY (@Biotechnology) experienced а +0.15% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -1.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
Reported Earning Dates
INCY is expected to report earnings on Apr 28, 2026.
JNJ is expected to report earnings on Apr 14, 2026.
Industries' Descriptions
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INCY | JNJ | INCY / JNJ | |
| Capitalization | 19.1B | 574B | 3% |
| EBITDA | 1.76B | 41.1B | 4% |
| Gain YTD | -2.734 | 15.838 | -17% |
| P/E Ratio | 14.99 | 21.62 | 69% |
| Revenue | 5.14B | 94.2B | 5% |
| Total Cash | 3.58B | 20.1B | 18% |
| Total Debt | 40.4M | 47.9B | 0% |
INCY | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 9 | |
SMR RATING 1..100 | 32 | 27 | |
PRICE GROWTH RATING 1..100 | 48 | 42 | |
P/E GROWTH RATING 1..100 | 100 | 78 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (70) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than INCY’s over the last 12 months.
JNJ's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (72) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than INCY’s over the last 12 months.
JNJ's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as INCY (32) in the Biotechnology industry. This means that JNJ’s stock grew similarly to INCY’s over the last 12 months.
JNJ's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as INCY (48) in the Biotechnology industry. This means that JNJ’s stock grew similarly to INCY’s over the last 12 months.
JNJ's P/E Growth Rating (78) in the Pharmaceuticals Major industry is in the same range as INCY (100) in the Biotechnology industry. This means that JNJ’s stock grew similarly to INCY’s over the last 12 months.
| INCY | JNJ | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 63% | N/A |
| Stochastic ODDS (%) | 1 day ago 62% | 1 day ago 52% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 47% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 52% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 40% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 42% |
| Advances ODDS (%) | 3 days ago 61% | 3 days ago 44% |
| Declines ODDS (%) | 5 days ago 59% | 5 days ago 41% |
| BollingerBands ODDS (%) | 1 day ago 61% | N/A |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 34% |
Advertisement
INCY and
Correlation & Price change
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with BMRN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then BMRN could also see price increases.
| Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
|---|---|---|---|---|
| INCY | 100% | -0.92% | ||
| BMRN - INCY | 43% Loosely correlated | -3.14% | ||
| PTCT - INCY | 41% Loosely correlated | -3.05% | ||
| GMAB - INCY | 41% Loosely correlated | -0.11% | ||
| TECH - INCY | 39% Loosely correlated | -0.05% | ||
| ROIV - INCY | 39% Loosely correlated | -0.95% | ||
More | ||||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.